Cargando…

Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review

COVID-19 is considered as the third human coronavirus and has a high potential for transmission. Fast public health interventions through antibodies, anti-virals or novel vaccine strategies to control the virus and disease transmission have been extremely followed. SARS-CoV-2 shares about 79% genomi...

Descripción completa

Detalles Bibliográficos
Autores principales: SHEIKHSHAHROKH, Amirhossein, RANJBAR, Reza, SAEIDI, Elnaz, SAFARPOOR DEHKORDI, Farhad, HEIAT, Mohammad, GHASEMI-DEHKORDI, Payam, GOODARZI, Hamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266011/
https://www.ncbi.nlm.nih.gov/pubmed/34268202
http://dx.doi.org/10.18502/ijph.v49iS1.3666
_version_ 1783719851982848000
author SHEIKHSHAHROKH, Amirhossein
RANJBAR, Reza
SAEIDI, Elnaz
SAFARPOOR DEHKORDI, Farhad
HEIAT, Mohammad
GHASEMI-DEHKORDI, Payam
GOODARZI, Hamed
author_facet SHEIKHSHAHROKH, Amirhossein
RANJBAR, Reza
SAEIDI, Elnaz
SAFARPOOR DEHKORDI, Farhad
HEIAT, Mohammad
GHASEMI-DEHKORDI, Payam
GOODARZI, Hamed
author_sort SHEIKHSHAHROKH, Amirhossein
collection PubMed
description COVID-19 is considered as the third human coronavirus and has a high potential for transmission. Fast public health interventions through antibodies, anti-virals or novel vaccine strategies to control the virus and disease transmission have been extremely followed. SARS-CoV-2 shares about 79% genomic similarity with SARS-CoV and approximately 50% with MERS-CoV. Based on these similarities, prior knowledge in treating SARS-CoV and MERS-CoV can be used as the basis of majority of the alternatives for controlling SARS-CoV-2. Immunotherapy is an effective strategy for clinical treatment of infectious diseases such as SARS-CoV-2. Passive antibody therapy, which decreases the virus replication and disease severity, is assessed as an effective therapeutic approach to control SARS-CoV-2 epidemics. The close similarity between SARS-CoV-2 genome with the SARS-CoV genome caused both coronaviruses to bind to the same angiotensin-converting enzyme 2 (ACE2) receptors that found in the human lung. There are several strategies to develop SARS-CoV-2 vaccines, which the majority of them are based on those developed previously for SARS-CoV. The interaction between the spike (S) protein of SARS-CoV-2 and ACE2 on the host cell surface leads to the initiation of SARS-CoV-2 infection. S protein, which is the main inducer of neutralizing antibodies, has been targeted by most of these strategies. Vaccines that induce an immune response against the S protein to inhibit its binding with the host ACE2 receptor, can be considered as effective vaccines against SARS-CoV-2. Here, we aimed to review frontier therapeutics and vaccination strategies for SARS-CoV-2 (COVID-19).
format Online
Article
Text
id pubmed-8266011
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-82660112021-07-14 Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review SHEIKHSHAHROKH, Amirhossein RANJBAR, Reza SAEIDI, Elnaz SAFARPOOR DEHKORDI, Farhad HEIAT, Mohammad GHASEMI-DEHKORDI, Payam GOODARZI, Hamed Iran J Public Health Review Article COVID-19 is considered as the third human coronavirus and has a high potential for transmission. Fast public health interventions through antibodies, anti-virals or novel vaccine strategies to control the virus and disease transmission have been extremely followed. SARS-CoV-2 shares about 79% genomic similarity with SARS-CoV and approximately 50% with MERS-CoV. Based on these similarities, prior knowledge in treating SARS-CoV and MERS-CoV can be used as the basis of majority of the alternatives for controlling SARS-CoV-2. Immunotherapy is an effective strategy for clinical treatment of infectious diseases such as SARS-CoV-2. Passive antibody therapy, which decreases the virus replication and disease severity, is assessed as an effective therapeutic approach to control SARS-CoV-2 epidemics. The close similarity between SARS-CoV-2 genome with the SARS-CoV genome caused both coronaviruses to bind to the same angiotensin-converting enzyme 2 (ACE2) receptors that found in the human lung. There are several strategies to develop SARS-CoV-2 vaccines, which the majority of them are based on those developed previously for SARS-CoV. The interaction between the spike (S) protein of SARS-CoV-2 and ACE2 on the host cell surface leads to the initiation of SARS-CoV-2 infection. S protein, which is the main inducer of neutralizing antibodies, has been targeted by most of these strategies. Vaccines that induce an immune response against the S protein to inhibit its binding with the host ACE2 receptor, can be considered as effective vaccines against SARS-CoV-2. Here, we aimed to review frontier therapeutics and vaccination strategies for SARS-CoV-2 (COVID-19). Tehran University of Medical Sciences 2020-10 /pmc/articles/PMC8266011/ /pubmed/34268202 http://dx.doi.org/10.18502/ijph.v49iS1.3666 Text en Copyright © 2020 Sheikhshahrokh et al. Published by Tehran University of Medical Sciences https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
spellingShingle Review Article
SHEIKHSHAHROKH, Amirhossein
RANJBAR, Reza
SAEIDI, Elnaz
SAFARPOOR DEHKORDI, Farhad
HEIAT, Mohammad
GHASEMI-DEHKORDI, Payam
GOODARZI, Hamed
Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review
title Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review
title_full Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review
title_fullStr Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review
title_full_unstemmed Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review
title_short Frontier Therapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review
title_sort frontier therapeutics and vaccine strategies for sars-cov-2 (covid-19): a review
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266011/
https://www.ncbi.nlm.nih.gov/pubmed/34268202
http://dx.doi.org/10.18502/ijph.v49iS1.3666
work_keys_str_mv AT sheikhshahrokhamirhossein frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview
AT ranjbarreza frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview
AT saeidielnaz frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview
AT safarpoordehkordifarhad frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview
AT heiatmohammad frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview
AT ghasemidehkordipayam frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview
AT goodarzihamed frontiertherapeuticsandvaccinestrategiesforsarscov2covid19areview